Onco Actu du 15 janvier 2016

	3.1 Tabac
How public health cuts could leave Stop Smoking Services under threat [Cancer Research UK] We’re really worried about the future of Stop Smoking Services. But, crucially, we think there could be a way to get those budgets looking healthy again, helping more people quit smoking. And it comes from making those who’ve inflicted the damage – the tobacco companies – pay for it.
How shaky are the twin pillars of the case for e-cigarettes? [The Conversation] Many e-cigarettes advocates are utterly convinced that vaping is highly effective at getting people off smoking, and of negligible health risk. It would be wonderful if they were right on both counts. These two papers should serve as a major amber light to such unbridled enthusiasm.
E-cigarettes lower the odds of quitting successfully, contested study claims [The Guardian] US researchers say that the “vaping” devices keep people smoking conventional cigarettes for longer, though experts were scathing about the findings.
	4.12 Biopsies liquides
Matter: Searching for Cancer Maps in Free-Floating DNA [NY Times] Unfortunately, the genetic sequence of a piece of cell-free DNA doesn’t tell researchers where in the body it originated — a valuable clue for doctors looking for diseases. “Knowing the origin of circulating DNA is of great importance,” said Alain R. Thierry, director of research at France’s National Institute of Health and Medical Research.
	5. Traitements
Doubt over high-pressure oxygen for radiotherapy-induced gastrointestinal symptoms [The Institute of Cancer Research] The findings, published in The Lancet Oncology, challenge existing evidence for current practice and highlight an “urgent need” for further high-quality research to determine the value of hyperbaric oxygen as a standard of care, according to study authors.
Study finds how diabetes drug metformin inhibits progression of pancreatic cancer [Massachusetts General Hospital] Metformin-induced suppression of metastasis-promoting tumor microenvironment may be most prevalent in overweight, obese patients.
	5.10 Traitements - Essais
Progress and Collaboration on Clinical Trials [FDA Voice] In August, FDA published an Action Plan designed to address three specific priorities: improving the quality and comprehensiveness of demographic subgroup data collection, reporting and analysis; identifying and eliminating barriers for increased participation in clinical trials; and improving the transparency of subgroup data.
Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk [Institute of Medicine] In its report, Sharing Clinical Trial Data: Maxi­mizing Benefits, Minimizing Risk, the committee concludes that sharing data is in the public interest, but a multi-stakeholder effort is needed to develop a culture, infrastructure, and policies that will foster responsible sharing—now and in the future.
	5.3 Traitements - FDA, EMA,...
Handling competing interests: revised rules for Management Board members [EMA] The Agency will apply a ‘risk-based’ approach, to determine the level of involvement in activities of the Management Board for a Board member with a declared interest.
F.D.A. Faulted for Problems With Drug Tracking [NY Times] “F.D.A.’s data on post-market safety issues and studies were found to be incomplete, outdated, to contain inaccuracies, and to be stored in a manner that made routine, systematic analysis difficult,” the accountability office concluded in its report.
	5.4 Traitements - Economie
NIH asked to override patent on cancer drug due to price [STAT] In their view, the Xtandi patent should be overridden because Xtandi was developed at the University of California, Los Angeles, with help from taxpayer dollars — specifically, NIH and Department of Defense grants.
	6. Lutte contre les cancers
'New research hope' from pancreatic cancer tissue bank [BBC News] Samples will be collected from consenting patients at six hospitals - in Swansea, Leicester, Oxford and Southampton and Barts and the Royal Free in London.
	6.1 Observation
American Cancer Society Launches New Cancer Statistics Web Site [ACS] The mobile and tablet friendly Cancer Statistics Center website creates a brand new way for readers to explore, interact with, and share cancer statistics.
Delayed deaths declining among pediatric cancer survivors [Reuters] The analysis of 34,033 patients whose cancers were diagnosed before age 21 and who survived to the five-year mark found that the odds of death from any cause, including due to a recurrence or progression of a cancer, declined for children treated in the 1980s compared to those treated in the 1970s.
	6.10 Politiques
Why Curing Cancer Is Not a ‘Moonshot’ [TIME] The shopworn metaphor actually makes the challenge seem easier than it is.
How to tell if 'cancer moonshot' is legit, or political rhetoric [STAT] "We figured out that if you keep going to the same scientists and the same thought leaders, nothing is going to change: they’re very invested in continuing to do what they’ve been doing.” A cancer moonshot will have to make some people mad.
Dear Mr. President: Please stop with these science “moonshots” [Ars Technica] Science needs steady sustainable boring growth, not flashy ill-formed initiatives.
How Obama's cancer 'moonshot' can save many lives [CNN] I like the moonshot analogy. We need a concerted, organized effort with a leader and a goal.
	6.5 Médecines alternatives
Well: Straddling Conventional and Alternative Cancer Treatment [NY Times] When Dr. Nicholas Gonzalez died in July, there was not much notice. He did not get an obituary in The New York Times or in most other major media outlets. Yet Dr. Gonzalez, whom I interviewed in 2003, was a fascinating figure in the world of cancer, walking a tenuous boundary between orthodox oncology and alternative medicine — or what is now called complementary medicine.
	6.6 Publications
Who Is John Ioannidis? [Mendelspod] It’s now been over ten years since John Ioannidis published his now famous paper, Why Most Published Research Findings Are False. What response has John seen from the scientific community? How has the paper changed his career and role in the scientific community?
	6.9 Controverses
Paul Glasziou and Iain Chalmers: Is 85% of health research really “wasted”? [BMJ Blogs] If research was a transport business, we would be appalled by these data. Half the goods carried would be badly designed, half lost in shipping, and half of the remainder broken by the time they arrived—a truly heart breaking waste. The “good news” is that there is vast potential gain from salvage operations!